Table 1 Comparison of variables with 12-chemokine gene signature
N (%) | |||||
|---|---|---|---|---|---|
Variable | Level | Total | Low 12-chemokine | High 12-chemokine | p value |
Race | White | 331 (90.4%) | 159 (86.9%) | 172 (94%) | 0.03 |
Not white | 35 (9.6%) | 24 (13.1%) | 11 (6%) | ||
Histology | Ductal | 284 (77.6%) | 136 (74.3%) | 148 (80.9%) | 0.371 |
Lobular | 52 (14.2%) | 30 (16.4%) | 22 (12%) | ||
Others | 30 (8.2%) | 17 (9.3%) | 13 (7.1%) | ||
Tumor grade | Well differentiated | 36 (10.1%) | 26 (14.9%) | 10 (5.6%) | <0.0001 |
Moderately differentiated | 148 (41.7%) | 90 (51.4%) | 58 (32.2%) | ||
Poorly/undifferentiated | 171 (48.2%) | 59 (33.7%) | 112 (62.2%) | ||
Cancer status | Free (NED) | 274 (82.5%) | 138 (83.6%) | 136 (81.4%) | 0.668 |
Not free of tumor | 58 (17.5%) | 27 (16.4%) | 31 (18.6%) | ||
TNM stage | 1 | 95 (27.9%) | 49 (29.2%) | 46 (26.7%) | 0.709 |
2 | 176 (51.8%) | 83 (49.4%) | 93 (54.1%) | ||
3 | 69 (20.3%) | 36 (21.4%) | 33 (19.2%) | ||
Any adjuvant treatment | No | 49 (13.5%) | 23 (12.7%) | 26 (14.3%) | 0.755 |
Yes | 314 (86.5%) | 158 (87.3%) | 156 (85.7%) | ||
Receptor status | (ER+ or PR+)/(HER2- or HER2 missing) | 212 (63.5%) | 121 (72.9%) | 91 (54.2%) | 0.001 |
ER-/PR-/(HER2- or missing) | 67 (20.1%) | 26 (15.7%) | 41 (24.4%) | ||
HER2+ | 55 (16.5%) | 19 (11.4%) | 36 (21.4%) | ||
Survival status | Alive | 263 (71.9%) | 133 (72.7%) | 130 (71%) | 0.82 |
Dead | 103 (28.1%) | 50 (27.3%) | 53 (29%) | ||
Recurrence status | No recurrence | 272 (76.6%) | 130 (73%) | 142 (80.2%) | 0.133 |
Recurrence | 83 (23.4%) | 48 (27%) | 35 (19.8%) | ||